134 related articles for article (PubMed ID: 24014028)
1. Dynamic analysis of the epidermal growth factor (EGF) receptor-ErbB2-ErbB3 protein network by luciferase fragment complementation imaging.
Macdonald-Obermann JL; Adak S; Landgraf R; Piwnica-Worms D; Pike LJ
J Biol Chem; 2013 Oct; 288(42):30773-30784. PubMed ID: 24014028
[TBL] [Abstract][Full Text] [Related]
2. An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation.
Schoeberl B; Faber AC; Li D; Liang MC; Crosby K; Onsum M; Burenkova O; Pace E; Walton Z; Nie L; Fulgham A; Song Y; Nielsen UB; Engelman JA; Wong KK
Cancer Res; 2010 Mar; 70(6):2485-94. PubMed ID: 20215504
[TBL] [Abstract][Full Text] [Related]
3. Examining the protective role of ErbB2 modulation in human-induced pluripotent stem cell-derived cardiomyocytes.
Eldridge S; Guo L; Mussio J; Furniss M; Hamre J; Davis M
Toxicol Sci; 2014 Oct; 141(2):547-59. PubMed ID: 25055963
[TBL] [Abstract][Full Text] [Related]
4. The natural compound fucoidan from New Zealand Undaria pinnatifida synergizes with the ERBB inhibitor lapatinib enhancing melanoma growth inhibition.
Thakur V; Lu J; Roscilli G; Aurisicchio L; Cappelletti M; Pavoni E; White WL; Bedogni B
Oncotarget; 2017 Mar; 8(11):17887-17896. PubMed ID: 28060735
[TBL] [Abstract][Full Text] [Related]
5. ErbB2 resembles an autoinhibited invertebrate epidermal growth factor receptor.
Alvarado D; Klein DE; Lemmon MA
Nature; 2009 Sep; 461(7261):287-91. PubMed ID: 19718021
[TBL] [Abstract][Full Text] [Related]
6. Computational and Experimental Characterization of Patient Derived Mutations Reveal an Unusual Mode of Regulatory Spine Assembly and Drug Sensitivity in EGFR Kinase.
Ruan Z; Katiyar S; Kannan N
Biochemistry; 2017 Jan; 56(1):22-32. PubMed ID: 27936599
[TBL] [Abstract][Full Text] [Related]
7. Protein kinase A-mediated gating of neuregulin-dependent ErbB2-ErbB3 activation underlies the synergistic action of cAMP on Schwann cell proliferation.
Monje PV; Athauda G; Wood PM
J Biol Chem; 2008 Dec; 283(49):34087-100. PubMed ID: 18799465
[TBL] [Abstract][Full Text] [Related]
8. Feedback activation of HER3 attenuates response to EGFR inhibitors in colon cancer cells.
Bosch-Vilaró A; Jacobs B; Pomella V; Abbasi Asbagh L; Kirkland R; Michel J; Singh S; Liu X; Kim P; Weitsman G; Barber PR; Vojnovic B; Ng T; Tejpar S
Oncotarget; 2017 Jan; 8(3):4277-4288. PubMed ID: 28032592
[TBL] [Abstract][Full Text] [Related]
9. HER2 signaling regulates HER2 localization and membrane retention.
Jeong J; Kim W; Kim LK; VanHouten J; Wysolmerski JJ
PLoS One; 2017; 12(4):e0174849. PubMed ID: 28369073
[TBL] [Abstract][Full Text] [Related]
10. Betacellulin (BTC) Biases the EGFR To Dimerize with ErbB3.
Rush JS; Peterson JL; Ceresa BP
Mol Pharmacol; 2018 Dec; 94(6):1382-1390. PubMed ID: 30249613
[TBL] [Abstract][Full Text] [Related]
11. Transcriptionally inducible Pleckstrin homology-like domain, family A, member 1, attenuates ErbB receptor activity by inhibiting receptor oligomerization.
Magi S; Iwamoto K; Yumoto N; Hiroshima M; Nagashima T; Ohki R; Garcia-Munoz A; Volinsky N; Von Kriegsheim A; Sako Y; Takahashi K; Kimura S; Kholodenko BN; Okada-Hatakeyama M
J Biol Chem; 2018 Feb; 293(6):2206-2218. PubMed ID: 29233889
[TBL] [Abstract][Full Text] [Related]
12. Spleen tyrosine kinase activity regulates epidermal growth factor receptor signaling pathway in ovarian cancer.
Yu Y; Suryo Rahmanto Y; Shen YA; Ardighieri L; Davidson B; Gaillard S; Ayhan A; Shi X; Xuan J; Wang TL; Shih IM
EBioMedicine; 2019 Sep; 47():184-194. PubMed ID: 31492560
[TBL] [Abstract][Full Text] [Related]
13. Geldanamycin selectively targets the nascent form of ERBB3 for degradation.
Gerbin CS; Landgraf R
Cell Stress Chaperones; 2010 Sep; 15(5):529-44. PubMed ID: 20084478
[TBL] [Abstract][Full Text] [Related]
14. Different EGF-induced receptor dimer conformations for signaling and internalization.
Haubrich J; Zwier JM; Charrier-Savournin F; Prézeau L; Pin JP
FASEB J; 2024 Jan; 38(1):e23356. PubMed ID: 38071470
[TBL] [Abstract][Full Text] [Related]
15. Dual inhibition of both the epidermal growth factor receptor and erbB2 effectively inhibits the promotion of skin tumors during two-stage carcinogenesis.
Kiguchi K; Kitamura T; Moore T; Rumi M; Chang HC; Treece D; Ruffino L; Connolly K; DiGiovanni J
Cancer Prev Res (Phila); 2010 Aug; 3(8):940-52. PubMed ID: 20682802
[TBL] [Abstract][Full Text] [Related]
16. Inhibition by transmembrane peptides of chimeric insulin receptors.
Bennasroune A; Gardin A; Auzan C; Clauser E; Dirrig-Grosch S; Meira M; Appert-Collin A; Aunis D; Crémel G; Hubert P
Cell Mol Life Sci; 2005 Sep; 62(18):2124-31. PubMed ID: 16132228
[TBL] [Abstract][Full Text] [Related]
17. Activation of EGF receptor family members suppresses the cytotoxic effects of tumor necrosis factor-alpha.
Hoffmann M; Schmidt M; Wels W
Cancer Immunol Immunother; 1998 Nov; 47(3):167-75. PubMed ID: 9829842
[TBL] [Abstract][Full Text] [Related]
18. Transmembrane peptides as inhibitors of ErbB receptor signaling.
Bennasroune A; Fickova M; Gardin A; Dirrig-Grosch S; Aunis D; Crémel G; Hubert P
Mol Biol Cell; 2004 Jul; 15(7):3464-74. PubMed ID: 15146055
[TBL] [Abstract][Full Text] [Related]
19. Emerging anti-cancer antibodies and combination therapies targeting HER3/ERBB3.
Gaborit N; Lindzen M; Yarden Y
Hum Vaccin Immunother; 2016 Mar; 12(3):576-92. PubMed ID: 26529100
[TBL] [Abstract][Full Text] [Related]
20. A small molecule inhibitor of HER3: a proof-of-concept study.
Colomba A; Fitzek M; George R; Weitsman G; Roberts S; Zanetti-Domingues L; Hirsch M; Rolfe DJ; Mehmood S; Madin A; Claus J; Kjaer S; Snijders AP; Ng T; Martin-Fernandez M; Smith DM; Parker PJ
Biochem J; 2020 Sep; 477(17):3329-3347. PubMed ID: 32815546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
